UBS reiterated a Buy rating on AMN Healthcare Services (NYSE: AHS), and raised the price target to $48.50 (from $42.00). following the company's 2Q earnings report. EPS of $0.61 was $0.09 ahead of consensus estimates. Revenues grew to $474M, beating the Street by $18M.

Analyst A.J. Rice commented, "AHS posted 2Q adj. cash EPS of $0.61, up 60% Y/Y and $0.09 ahead of UBSe/cons. 2Q16 revs grew 35% Y/Y (19% organic) to $474 mln, $20/$18 mln ahead of UBSe/cons. Adj EBITDA margin improved 130 bps Y/Y to 12.5%, 100 bps above UBSe. Higher revs/strong margins drove a 51% Y/Y increase in adj EBITDA to $59.3 mln, $7.0 mln above UBSe. Overall, the qtr's results, the 3Q16 outlook, and management's tone on the 2Q call suggest demand for AHS's medical staffing services remain very strong."

For an analyst ratings summary and ratings history on AMN Healthcare Services click here. For more ratings news on AMN Healthcare Services click here.

Shares of AMN Healthcare Services closed at $41.93 yesterday.